Introduction
Protein kinase C (PKC) is a family of serine/threonine protein kinases. Eleven isoforms have been described with varying dependencies on calcium, lipids and cofactors for activation (Dekker and Parker, 1994) . PKCs are also regulated by phosphorylation. Prior to activation, PKC (a and bII) undergoes transphorylations and autophosphorylations on serine and threonine residues to create a catalytically competent enzyme as well as to in¯uence PKC's subcellular localization (Newton, 1995) . Upon activation by diacylglycerol and phospholipid co-factors, PKC undergoes further autophosphorylation on serine and threonine residues Mitchell et al., 1989) . A number of PKC isoforms, including d, e, Z, x (Denning et al., 1996) and a, b, g (Gschwendt et al., 1994) can also be phosphorylated on tyrosine residues in vitro. However, PKC d is the only PKC isoform to undergo phosphorylation on tyrosine in vivo (Li et al., 1994a; Gschwendt et al., 1994) and is the only PKC isoform whose kinase activity is in¯uenced by tyrosine phosphorylation (Gschwendt et al., 1994) . All reports are in agreement with the fact that PKC d is phosphorylated on tyrosine in response to in vivo agonist treatment or PMA (Li et al., 1994a; Denning et al., 1993 Denning et al., , 1996 Gschwendt et al., 1994) . However, the eect that this modi®cation has on PKC d catalytic activity remains controversial (Denning et al., 1993; Gschwendt et al., 1994; Haleem-Smith et al., 1995) . In this report, we show a dissociation between tyrosinephosphorylated PKC d and catalytically active PKC d in MCF-7 cells treated with PMA.
Although the tyrosine kinase responsible for phosphorylating PKC d in phorbol ester-treated cells has not been identi®ed, studies have strongly implicated Src (Li et al., 1994a; Gschwendt et al., 1994; Denning et al., 1996) . PKC d is activated in v-Src transformed ®broblasts (Zang et al., 1995) , Src can be activated on phorbol ester treatment of cells (Rodriquez-Fernandez et al., 1996) and Src has been shown to phosphorylate PKC d in in vitro kinase assays (Gschwendt et al., 1994; Denning et al., 1996) , and the in vivo association of PKC d with v-Src has been demonstrated in v-Src transformed ®broblasts (Zang et al., 1997) . In light of these data, we determined whether we could detect an in vivo association of Src and PKC d in an eort to further substantiate Src as a tyrosine kinase responsible for the tyrosine phosphorylation of PKC d in MCF-7 cells. We detected the PMA-dependent activation of Src and the PMA-dependent association of active Src with PKC d in MCF-7 cells.
Results and discussion
We were ®rst interested to determine if PKC d was phosphorylated on tyrosine upon phorbol 12-myristate 13-acetate (PMA)-stimulated PKC activation in MCF-7 cells. MCF-7 cells were treated without or with 50 nM PMA for 10 min, cells were harvested, and cytosolic (C) and Triton X-100 soluble (TS) membrane extracts were prepared. PKC d was immunoprecipitated from C and TS cell extracts, and immunoprecipitates were subjected to Western blot analyses. PKC d in untreated cells was equally distributed between the C and TS fractions (Figure 1a) . In PMA-treated cells, the ratio of PKC d content in TS versus C fractions was higher compared to vehicle-treated cells, consistent with translocation of PKC d from cytosol to particulate fractions in response to PMA, i.e., activation of PKC d. PMA also promoted a modest down-regulation of PKC d protein, a common response to PKCs following activation (Stabel and Parker, 1991) resulting from (often directed) proteolysis (Emoto et al., 1995; deVente et al., 1996) . To determine the localization of tyrosine-phosphorylated PKC d, a phospho-tyrosine Western on PKC d immunoprecipitates was performed. PKC d showed increased tyrosine phosphorylation in response to PMA treatment; however, tyrosine-phosphorylated PKC d was localized exclusively to C fractions of PMA-treated cells (Figure 1b) . In other reports, tyrosine-phosphorylated PKC d has been localized to the membrane fraction (Denning et al., 1993; Haleem-Smith et al., 1995; Solto and Toker, 1995; Zang et al., 1997) . While it is possible that the PKC d which translocated to TS fractions in response to PMA treatment may have been selectively dephosphorylated by a tyrosine phosphatase during membrane extraction, we do not think this is likely as the extraction buer contained sodium vanadate, a non-speci®c tyrosine phosphatase inhibitor.
We next sought to determine whether enzymaticallyactive PKC d was localized to the TS and/or C fractions of PMA-treated cells. In order to measure the in vivo activation of PKC d in response to in vivo PMA treatment, PKC d immunoprecipitates were subjected to an immunecomplex kinase assay. This assay measures the ability of PKC d to phosphorylate recombinant heat shock protein 25 (rHSP25), a selective substrate for PKC d (Maizels ET, et al. manuscript in publication) which is phosphorylated in PMA-treated MCF-7 cells (Faucher et al., 1993) , in an in vitro immunecomplex kinase assay. The PKC activity measured in this assay re¯ects the endogenous activation of PKC d as activating co-factors are not added to the assay. This assay is based on a report by Ohmichi et al. (1993) , in which the endogenous activation of PKC e was measured in cells treated with PMA, and immunoprecipitated PKC e activity was assayed in vitro in the absence of added co-factors. Maintenance of the active state of PKC d through the immunoprecipitation steps and assay has been demonstrated for recombinant PKD d activated in vitro by lipids and diacylglycerol (Peters CA et al. manuscript in preparation) .
PKC d immunoprecipitated from TS fractions of PMA-treated cells exhibited increased phosphorylation of rHSP25 (equivalent results were obtained using myelin basic protein as the substrate, although the fold activation was often less than that with rHSP25), over that from TS fractions of vehicle-treated cells, consistent with translocation of PKC d into TS fractions and activation of PKC d with PMA treatment of MCF-7 cells (Figure 1c ). PMA-activated PKC d in the TS fraction, however, was not tyrosinephosphorylated (Figure 1b) . These results show that there is a dissociation between tyrosine-phosphorylated PKC d (in C fraction) and catalytically active PKC d (in TS fraction).
While it is well-documented that PKC d is phosphorylated on tyrosine upon PMA or agonist treatment of cells, the eect of tyrosine phosphorylation on PKC d kinase activity is controversial (Gschwendt et al., 1994; Li et al., 1994a; Denning et al., 1993; Solto and Toker 1995; Haleem-Smith et al., 1995; Li et al., 1994b) . For example, v-ras Ha transformed and TGF-a-treated keratinocytes showed increased tyrosine phosphorylation of PKC d which correlated with decreased PKC d enzymatic activity (Denning et al., 1996) while PMA treated 32D cells showed increased tyrosine phosphorylation of PKC d and increased PKC d kinase activity in an in vitro kinase assay towards a PKC d pseudosubstrate peptide (Li et al., 1994a) . There is also evidence that the catalytic activity of tyrosine-phosphorylated PKC d may depend on the substrate. For example, antigen activation of the immunoglobulin E receptor and consequently tyrosine-phosphorylated PKC d exhibited decreased activity towards the IgE receptor g chain peptide but not towards histone or myelin basic protein peptide (Haleem-Smith et al., 1995) . The sites of tyrosine phosphorylation on PKC d may also dier and may contribute to distinct eects of PKC d on substrates (Li et al., 1996; Szallasi et al., 1995) .
While we detected an increase in the tyrosine phosphorylation of PKC d in an activator (PMA)-dependent manner, our extraction buer (the presence of the tyrosine-phosphorylated PKC d in the cytosolic fraction following PMA treatment of MCF-7 cells likely resulted from the composition of our extraction buer (especially MG 2+ levels) since it has been shown that the localization of PKC d is aected by Mg 2+ levels in the buer (Lehel et al., 1994; Cutler et al., 1993) ), resulted in the unique separation of tyrosinephosphorylated PKC d and catalytically-active PKC d. Although we do not know if the tyrosine phosphorylation of PKC d precedes or follows translocation and subsequent activation of PKC d, our ability to separate tyrosine-phosphorylated PKC d from active PKC d demonstrates that PKC d activity (following immuneprecipitation) is independent of the presence of its tyrosine phosphorylation. Although the tyrosine kinase which phosphorylates PKC d in vivo has not been identi®ed, Src is a good candidate. Src more eectively phosphorylates PKC d in an in vitro kinase assay compared to Fyn and the EGF receptor (Gschwendt et al., 1994) , and immunodepletion of Src and Fyn from cellular extracts reduces immunodetectible tyrosine-phosphorylated PKC d (Denning et al., 1996) . PKC d is activated in v-Src transformed ®broblasts (Zang et al., 1995) and recently, the in vivo association of PKC d with v-Src in v-Src transformed ®broblasts has been demonstrated (Zang et al., 1997) .
Based on these reports we sought to determine if we could detect an in vivo association between Src and PKC d in MCF Figure  3a) . The amount of total Src immunoprecipitated from C and TS fractions is shown in Figure 3b . While Src is generally believed to be localized primarily to plasma membranes, previous studies clearly show its presence in cytosolic fractions (Redmond et al., 1992; Walker et al., 1993; Owen et al., 1996) , consistent with our results. These results demonstrate that PMA stimulated the in vivo association of PKC d with Src, coincident with the localization of tyrosine-phosphorylated PKC d in the C fraction of the cells.
To determine if the Src that was associated with PKC d in the C fraction was active and therefore capable of phosphorylating PKC d, we determined the levels of active Src in Src immunoprecipitates. Dephosphorylation of Src on residue 530 promotes its kinase activity (Kawakatsu et al., 1996) . The antibody`clone 28', which is reactive only with Src de-phosphorylated on residue 530, i.e. active Src (Kawakatsu et al., 1996) , was used to evaluate the levels of active Src in total Src immunoprecipitates. Active Src levels were increased both in C and TS fractions of PMA-compared to vehicle-treated cells (Figure 3c ). Aligning the blots in Figure 3b and c revealed that the doublets (Figure 3b ) re¯ect inactive states of Src; immunoreactivity corresponding to active Src (Figure 3c ) migrated just below bands seen in Figure 3b and was not detected in thè total' Src western (Figure 3b ). This result indicates that a very small percentage of Src is activated and is also consistent with the multiple phosphorylation states of Src (Malarkey et al., 1995; Kosaka et al., 1996) . The increase in active Src in the C fraction coincided with increased tyrosine phosphorylation of a 78 kDa protein which co-migrated with PKC d in Src immunoprecipitates from the C fraction of PMA-treated cells ( Figure  3d ). These results show that while Src activity is increased in response to PMA treatment in both the C and TS fractions, Src association with PKC d (seen in Figure 3 ) is detected only in the C fraction.
We next performed a time course study to determine if the duration of PMA treatment aected the extent of Src association with PKC d. MCF-7 cells were treated with vehicle (for 60 min) or 10 nM PMA for 5, 20 or 60 min, Src was immunoprecipitated from NP-40 lysis buer extracts of MCF-7 cells, and Src immunoprecipitates were subjected to PKC d Westerns. As shown in (Li et al., 1994a; Gschwendt et al., 1994; Denning et al., 1996) , our results are consistent with the hypothesis that Src is the tyrosine kinase which phosphorylates PKC d in PMAtreated MCF-7 cells. Our demonstration of the in vivo association of active Src with PKC d in a cell line not transformed by Src supports a more physiological role for this association. Our results additionally show that while the association of Src and PKC d in the C fraction is correlated with the catalytic activity of PKC d in the TS fraction, the activity of PKC d towards the substrate rHSP25 does not require the presence of phosphorylated tyrosine on PKC d. Additional studies are required to determine whether the tyrosine phosphorylation of PKC d is an early event which occurs in vivo in response to PMA prior to the translocation of PKC d and formation of an enzymatically active conformation or whether the tyrosine phosphorylation of PKC d occurs subsequent to membrane activation, perhaps targeting the enzyme for degradation. Since activation of PKC d in various cellular models (Mischak et al., 1993; Watanabe et al., 1992; Mishima et al., 1994; Hirai et al., 1994) and PMA treatment of MCF-7 cells (Roos et al., 1986; Darbon et al., 1986; Issandou et al., 1988) both lead to growth inhibition, it will be very interesting to determine if PMA-dependent Src activation is required for PMA-dependent growth inhibition of MCF-7 breast cancer cells.
Materials and methods

Materials
The following materials were purchased: [g-32 P]ATP, ammonium salt (speci®c activity 3000 Ci/mmol) from Dupont-New England Nuclear (Boston, MA); nytran nylon membranes from Schleicher and Schuell (Keene, NH); ECL reagents and Hybond TM-ECL nitrocellulose membranes from Amersham Life Science (Arlington Heights, IL); media components from GIBCO-BRL Life Technologies (Gaithersburg, MD); SDS-polyacrylamide gel electrophoresis (PAGE) reagents and protein standards from Bio-Rad (Richmond, CA); recombinant murine HSP25 from StressGen (Victoria, BC). All other biochemical reagents were purchased from Sigma Chemical Co. (St Louis, MO), unless otherwise indicated.
Cell culture
MCF-7 cells were routinely maintained in RPMI 1640 media supplemented with 10% heat inactivated fetal calf serum (FCS) at 378C with 5% CO 2 . For all experiments, cells were switched to an`experimental medium', de®ned as phenol red-free minimal essential medium (MEM) containing Earle's salts and 5% heat inactivated FCS stripped twice with dextran-coated charcoal one day prior to the experimental treatment. Cells were harvested in Hank's balanced salt solution containing 1 mM EDTA.
Preparation of cytosol and membrane extracts
Harvested cells were collected by centrifugation and the cell pellet was washed with PBS lacking Ca 2+ and Mg 2+ .
Approximately 1610 7 cells were resuspended in protease phosphatase inhibitor buer A (10 mM potasium phosphate, 1 mM EDTA, 5 mM EGTA, 10 mM MgCl 2 , 2 mM dithiothreitol (DTT), 1 mM sodium orthovanadate, 80 mM b-glycerophosphate, 100 mg/ml pepstatin A (from 1 mg/ml stock in 100% ethanol), 10 mg/ml leupeptin and 40 mg/ml PMSF; pH 7.25) and homogenized in a ground glass homogenizer. The homogenate was centrifuged at 100 000 g for 70 min at 48C. The supernatant (cytosol) was removed and proteins in the supernatant denatured by addition of 36 stop solution (3% SDS, 150 mM Tris-HCl pH 6.8, 2.4 mM EDTA, 3% b-mercaptoethanol, 30% glycerol, 0.5% Bromphenol blue) and boiling in a water bath for 5 min. Triton X-100 solubilized pellet fractions were prepared by re-homogenizing the pellet in an equal volume of buer A containing 0.2% Triton X-100, stirring at 48C for 45 min, then centrifuging at 100 000 g for 30 min at 48C. This supernatant was then processed as described for the cytosolic fraction to now constitute the Triton X-100 solubilized membrane fraction. NP-40 lysis buer cell extracts were prepared by resuspending *1610 6 cells in 0.5 ml of lysis buer B (150 mM NaCl, 0.5% NP-40, 50 mM Tris-HCl pH 8.0, 5 mM EDTA, 100 mM NaF, 200 mM sodium orthovanadate, 0.5 mM dithiothreitol, 1 mM PMSF, 5 mM benzamidine HCl, 1 mg/ml pepstatin and 1 mg/ml leupeptin), incubating on ice for 5 min followed by sonication on ice for 1 min. Lysate was centrifuged at 14 000 g for 10 min at 48C and supernatant transferred to a fresh tube and processed as described above. Protein concentrations were determined (Lowry et al., 1951) and samples were normalized to the same concentration.
Western blot analysis
Samples in 36 stop solution were separated by SDS ± PAGE using an 8.5% or 10% acrylamide running gel and 5% acrylamide stacking gel. Western blot analysis was performed according to Burnette (1981) . The following antibodies were obtained: anti-PKC d from Transduction Laboratories (Lot #2 released 4/1995), anti v-src (Ab-1) from Calbiochem, 4G10 antiphosphotyrosine from Upstate Biotechnology, and clone 28 from Dr H Kawakatsu. HRPconjugated secondary antibody complexes were detected using ECL. Quantitation of bands was performed using the Fujix bioimaging analyzer BAS 2000 or the Molecular Analyst 2 /PC image analysis software for the Bio Rad model GS-670 densitometer.
Immunoprecipitation
Immunoprecipitations were performed from 500 ml of 1 mg/ml cytosolic or Triton X-100-solubilized pellet extracts by the addition of 1 mg of PKC d or v-Src antibody and incubation overnight at 48C. Immunecomplexes were separated by addition of 25 ml Protein A/G Plus-agarose (Santa Cruz Biotechnology), incubated 2 h and pelleted. Pellets were washed twice with 1 ml radioimmunoprecipitation assay (RIPA) buer (10 mM TrisHCl, pH 7.2, 150 mM NaCl, 1% deoxycholate, 1% Triton, 0.1% SDS, 1 mM Na orthovanadate, 1 mM PMSF) (Chen and Blenis, 1990) , once with TE (10 mM Tris, 0.1 mM EGTA, pH 7.5), and either mixed with 36SDS stop or subjected to an immunecomplex kinase assay.
Immunecomplex kinase assays
For PKC kinase assays, immunecomplexes were resuspended in 50 ml of TE and assayed in a reaction volume of 110 ml containing 50 mM a-glycerophosphate, 10 mM MgCl 2 , 1 mM DTT, 50 mg/ml rHSP25 and 5 mCi of 5 mM [g-32 P]ATP. Samples were incubated at 378C for 5 min and reaction terminated by addition of 36SDS stop solution and heat denaturation 5 min. Following SDS ± PAGE (loading 75 ml [50%] of the stopped sample on a 12% gel), the gel was cut at the 46 kDa MW marker. The lower portion was stained, destained, dried and exposed to ®lm at room temperature while the upper portion was transferred to nitrocellulose to perform Western blots. For Src kinase assays, immunecomplexes were assayed in a reaction volume of 35 ml containing 20 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 20 mCi of 5 mM [g-32 P]ATP and 5 mg per rection of acid denatured enolase (Cooper et al., 1984) . Samples were incubated at room temperature for 15 min, heat denatured, and the entire sample subjected to SDS ± PAGE. Separated proteins were transferred to nitrocellulose for ECL Western blotting and autoradiography of 32 Plabeled proteins.
